Carregant...
HOSPITAL INITIATED INJECTABLE OPIOID AGONIST THERAPY FOR THE TREATMENT OF SEVERE OPIOID USE DISORDER
BACKGROUND: Across North America, there is an unprecedented opioid overdose epidemic. Approximately 15% of individuals with severe opioid use disorder (OUD) do not benefit from opioid agonist therapy (OAT) such as buprenorphine/naloxone or methadone and are considered treatment refractory. Of those...
Guardat en:
| Publicat a: | J Addict Med |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7927900/ https://ncbi.nlm.nih.gov/pubmed/32769776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/ADM.0000000000000713 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|